Table 2.
Expression of PD-L2 before and after neoadjuvant chemotherapy
| Antibody | Antibody | |||
|---|---|---|---|---|
| #82723 | #18251-1-AP | |||
| Specimen of diagnostic biopsies before NCHT | (n = 33) | (%) | (n = 33) | (%) |
| PD-L2 expression in cancer cells | ||||
| 0 (0–4%) | 32 | (96.9) | 32 | (96.9) |
| 1+ (5–25%) | 1 | (3.1) | 1 | (3.1) |
| 2+ (26–50%) | 0 | 0 | 0 | 0 |
| 3+ (51–75%) | 0 | 0 | 0 | 0 |
| 4+ (76–100%) | 0 | 0 | 0 | 0 |
| PD-L2 expression in TILS | ||||
| 0 (0–4%) | 32 | (96.9) | 32 | (96.9) |
| 1+ (5–25%) | 1 | (3.1) | 1 | (3.1) |
| 2+ (26–50%) | 0 | 0 | 0 | 0 |
| 3+ (51–75%) | 0 | 0 | 0 | 0 |
| 4+ (76–100%) | 0 | 0 | 0 | 0 |
| Specimen of surgical resection after NCHT | (n = 40) | (%) | (n = 40) | (%) |
| PD-L2 expression in cancer cells | ||||
| 0 (0–4%) | 40 | (100) | 40 | (100) |
| 1+ (5–25%) | 0 | 0 | 0 | 0 |
| 2+ (26–50%) | 0 | 0 | 0 | 0 |
| 3+ (51–75%) | 0 | 0 | 0 | 0 |
| 4+ (76–100%) | 0 | 0 | 0 | 0 |
| PD-L2 expression in TILs | ||||
| 0 (0–4%) | 40 | (100) | 40 | (100) |
| 1+ (5–25%) | 0 | 0 | 0 | 0 |
| 2+ (26–50%) | 0 | 0 | 0 | 0 |
| 3+ (51–75%) | 0 | 0 | 0 | 0 |
| 4+ (76–100%) | 0 | 0 | 0 | 0 |
NCHT neoadjuvant chemotherapy, TILs tumor infiltrating lymphocytes, PD-L2 programmed death ligand 2